Jun An Lu
Direktor/Vorstandsmitglied bei EpimAb Biotherapeutics, Inc.
Profil
Jun An Lu currently works at EpimAb Biotherapeutics, Inc., as Director.
Mr. Lu also formerly worked at Inmyshow Digital Technology (Group) Co., Ltd., as Securities Representative.
Aktive Positionen von Jun An Lu
| Unternehmen | Position | Beginn |
|---|---|---|
EpimAb Biotherapeutics, Inc.
 EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jun An Lu
| Unternehmen | Position | Ende |
|---|---|---|
| INMYSHOW DIGITAL TECHNOLOGY(GROUP)CO.,LTD. | Investor Relations Kontakt | 26.01.2017 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INMYSHOW DIGITAL TECHNOLOGY(GROUP)CO.,LTD. | Commercial Services |
| Private Unternehmen | 1 |
|---|---|
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |